Pfizer may pick up ERTU SGLT2 in Spring, that's assuming that they digit heads in R&D actually get it by the FDA. 2nd detail for ELIQUIS team?
3Q IR call mentioned diabetes approval expected in December by FDA. Not sure what this means for the field force, is this a positive glimmer of hope?